Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation
Under the threshold of three times China's per capita GDP, osimertinib appears not to be cost-effective compared to dacomitinib.
Authors
- Xiangyu Zhang (ORCID: https://orcid.org/0000-0002-4858-5429)
- Dong Wang (ORCID: https://orcid.org/0000-0001-5137-0771)
- Ying Li (ORCID: https://orcid.org/0000-0001-5062-0230)
- Lili Su (ORCID: https://orcid.org/0000-0001-8764-2855)
- M Y Li (ORCID: https://orcid.org/0000-0002-6199-8180)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1080/14737167.2025.2518135
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wu Jieping Medical Foundation